

Table SII. Study quality ratings

Author, year (ref.)	1. Sample size	2. Grading of disease severity	3. Classification of subtypes	4a. Comparison group (s): healthy controls	4b. Comparison group (s): other disease	5. Specificity of HRQOL instrument	6. Well-defined eligibility criteria	7. Recruitment setting and time frame reported	8. Confirmation of diagnosis	9. Reported whether patients were in treatment	10. Demographic characteristic	11. Clinical characteristics	12. Age-sensitive HRQOL measurement	13. Data analysed within clearly defined age groups	14. Response rate reported	Total, sum	Percent (23=100%)
Balci et al., 2007 (63)	0	1	0	0	1	1	1	2	2	0	0	0	0	0	8	34.8	
Beattie & Lewis-Jones, 2006 (64)	1	1	0	0	1	1	1	2	2	0	0	0	0	0	10	43.5	
Bilgic et al., 2010 (33)	1	1	0	1	0	0	2	2	2	0	2	2	1	0	15	65.2	
Chang et al., 2008 (67)	2	0	0	0	0	1	1	2	2	1	0	0	0	0	9	39.1	
de Jager et al., 2011 (61)	0	1	0	0	0	1	1	2	2	0	2	0	0	0	7	30.4	
Gånemo et al., 2011 (50)	1	1	1	0	0	0	2	2	2	1	2	2	0	1	16	69.6	
van Geel et al., 2016 (60)	1	0	0	0	0	1	2	2	2	1	2	2	1	1	13	56.5	
Khawaja et al., 2015 (48)	0	1	1	0	0	1	2	2	2	0	2	0	0	0	13	56.5	
Landells et al., 2015 (62)	2	1	1	0	0	1	2	2	2	2	2	2	0	0	15	65.2	
Langley et al., 2011 (34)	2	1	1	1	1	1	2	2	2	0	2	1	0	1	18	72.3	
Lewis-Jones & Finlay, 1995 (25)	0	0	0	1	1	1	1	2	2	0	2	2	0	0	10	43.5	
Manzoni et al., 2012 (65)	0	1	0	1	1	1	2	2	2	0	0	0	0	0	9	39.1	
Matusiewicz et al., 2013 (66)	2	0	0	0	0	1	1	2	0	1	2	1	0	1	11	47.8	
Matterne & Apfelbacher, 2016 (46)	2	0	0	1	0	0	2	2	0	0	0	1	0	1	9	39.1	
Oostveen et al., 2012 (49)	2	1	0	0	0	1	2	2	2	1	2	2	1	1	16	69.6	
Papp et al., 2014 (35)	2	1	1	0	0	1	2	1	2	0	2	1	1	0	14	60.9	
Smidt et al., 2010 (47)	0	0	0	0	1	1	2	1	2	0	0	0	0	1	9	39.1	

Study quality criteria and scoring: 1) sample size, k (number of studies) <27: 0 k ≥27 1 k ≥84: 2 k ≥795: 3, 2) grading of clinical disease severity, no: 0 yes: 1, 3) classification of subtypes, no: 0 yes: 1, 4a) comparison with healthy controls, no: 0 yes: 1, 4b) comparison with other disease, no: 0 yes: 1, 5) specificity of HRQOL instrument, generic: 0, dermatology-specific: 1, psoriasis-specific: 2, 6) well-defined eligibility criteria, no: 0 partly: 1 yes: 2, 7) recruitment setting and period, no: 0 partly: 1 yes: 2, 8) confirmation of diagnosis, no: 0, by non-dermatologist physician or not specified: 1, by dermatologist/specialist: 2, 9) reports whether patients are in treatment, no: 0 yes: 1, 10) demographic characteristics, no: 0, partly: 1, yes: 2, 11) background clinical characteristics, no: no: 0, partly: 1, yes: 2, 12) age-sensitive HRQOL measurement (use of instrument with age-appropriate versions separating between children and adolescents), no: 0 yes: 1, 13) data analysed within clearly defined age groups (children vs. adolescents), no: 0 yes: 1, 14) response rate reported, no: 0 yes: 1.